MRE11 and cancer: Our group has shown that UBQLN4 determines the balance of DDR pathways through the degradation of MRE11A which leads to resistance to DNA damaging agents and sensitivity to poly (ADP-ribose) polymerase inhibitor (PARPi), such as Olaparib in specific cancers [7].